#USA #New York #Securities Class Action #Aldeyra Therapeutics #Faruqi and Faruqi

Aldeyra Therapeutics Faces Securities Class Action Deadline

Investors of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) are facing critical developments as Faruqi & Faruqi, LLP, a prominent national securities law firm, issues a reminder regarding the impending deadline for a securities class action lawsuit. The cutoff for investors to seek the role of lead plaintiff in this significant action is May 29, 2026.

The concern arises from potential claims against Aldeyra, particularly following the disclosure that the FDA rejected the company's New Drug Application (NDA) for reproxalap. This rejection has stemmed from findings of insufficient evidence of efficacy, highlighting that the clinical studies supporting reproxalap did not provide adequate and reliable results. This alarming news contributed to a staggering loss of over 70% in Aldeyra's stock price - plummeting from approximately $4.23 to $1.24 per share on March 17, 2026.

Faruqi & Faruqi has articulated that the lawsuit alleges other serious infractions; namely, that Aldeyra and its executives may have made false statements or omissions about the company's operations and potential, thereby drastically misleading investors. These misrepresentations heightened investor risk and obscured the true efficacy of Aldeyra's drug candidate for treating dry eye disease.

Investor concerns intensified after the FDA's Complete Response Letter also indicated that the results of the clinical trials for reproxalap were inconsistent and inconclusive in demonstrating the product's effectiveness. Initially hailed as a potential breakthrough treatment, the mounting evidence suggests otherwise, leaving investors wondering about the future prospects of their investments.

As part of the ongoing litigation, the law firm stresses the importance of stepping forward for those who have suffered losses as a result of Aldeyra's disclosures. James (Josh) Wilson, a senior partner at Faruqi & Faruqi, has encouraged affected investors to contact him directly. Those who acquired Aldeyra shares between November 3, 2023, and March 16, 2026, are particularly urged to examine their legal options in light of the ongoing class action lawsuit.

Faruqi & Faruqi has built a significant reputation since its inception in 1995, recovering hundreds of millions of dollars for investors and taking on many high-profile cases across the United States.

In addition to the call for action, the law firm welcomes any relevant information pertaining to Aldeyra's conduct. They are particularly keen on hearing from whistleblowers, former employees, or shareholders who may have insights that could aid the case. Investors are encouraged to explore further details regarding the class action lawsuit at Faruqi & Faruqi's dedicated website, and can also reach out through direct phone lines to ensure their interests are protected.

With the deadline for filing to become a lead plaintiff drawing near, affected investors must act promptly. Participation in the ongoing legal battle could be vital for those seeking to recoup potential losses brought on by the fallout from Aldeyra's unreliability in clinical trial data. The upcoming months will be crucial as this case develops, and the implications for Aldeyra’s future remain uncertain.

As the market awaits further statements from Aldeyra and potential legal updates, investors are encouraged to stay informed and engaged with the legal proceedings unfolding around this significant class action case. Keep watching this space for potential updates on Aldeyra’s situation and what it means for investors moving forward.